"A pioneer of digital therapeutics, Voluntis was the first such company to go public. Personally, and in the name of the entire Voluntis team, I would like to thank all of our new and historic shareholders for their faith in us. This investment of €30.1M will allow us to continue our commitment to patients and healthcare professionals, helping them better manage treatment in the hopes that this improves real-world efficacy." - Pierre Leurent, CEO of Voluntis